Antineoplastic therapies associated with venous thromboembolism: disproportionality analysis of the WHO database

Résumé fourni par la source

The risk of venous thromboembolic events (VTE) is elevated in patients with active cancer. Recent antineoplastic therapies, including immunotherapies and targeted therapies may further increase VTE risk, although evidence are limited. In March 2024, we conducted a disproportionality analysis using reporting odds ratios (Reporting-OR) in VigiBase®, the World Health Organization's pharmacovigilance database, to assess the association between 280 antineoplastic therapies approved by the Food and Drug Administration and/or the European Medicines Agency and VTE (symptomatic or not), defined as deep vein thrombosis and/or pulmonary embolism. Reporting-OR were adjusted (aReporting-OR) for case characteristics, including primary tumor site and metastatic status. A total of 37,803 VTE cases associated with at least one antineoplastic therapies were identified. We identified 19 antineoplastic therapies significantly associated with an increased reporting of VTE with nintedanib emerging as a newly recognized association. The strongest associations were observed for lenalidomide (aReporting-OR 3.64; 95%CI 3.47-3.82), bevacizumab (aReporting-OR 3.64; 95%CI 3.43-3.86) and cyproterone (aReporting-OR 3.52; 95%CI 2.55-4.87). The median time to VTE onset was 64 days (27-143), with 81% of VTE events occurring within the first six months after antineoplastic therapy initiation. Future studies should include antineoplastic therapies in VTE risk assessments and evaluate the management of VTE when recurrences occur under while under treatment. ClinicalTrial registration number: NCT04696250.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.